Inhibition of breast cancer growth and metastasis by a biomimetic peptide

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Lee, Esak ^a   Lee, Seung Jae ^a   Koskimaki, Jacob E ^a   Han, Zheyi ^a   Pandey, Niranjan B ^a   Popel, Aleksander S ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 4; CULTURE MEDIUM; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; BREAST NEOPLASMS; CELL ADHESION; CELL MOTION; CELL SURVIVAL; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; FEMALE; HUMAN; IC50; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHANGIOGENESIS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MOLECULAR GENETICS; MOLECULAR MIMICRY; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; SECONDARY; SYNTHESIS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN TYPE IV; CULTURE MEDIA, CONDITIONED; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHANGIOGENESIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES;

EID: 84923320908     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07139     Document Type: Article

References (51)

1. DeSantis, C.,Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. CA Cancer J Clin 64, 52-62 (2014
2. Shamloo, B. K. et al. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf 35, 507-518 (2012
3. Schoppmann, S. F. et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240, 306-312 (2004
4. Lee, E., Koskimaki, J. E., Pandey, N. B. & Popel, A. S. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 15, 112-124 (2013
5. Lee, E., Rosca, E. V., Pandey, N. B. & Popel, A. S. Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol 43, 1812-1821 (2011
6. Koskimaki, J. E. et al. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis 16, 159-170 (2013
7. Karagiannis, E. D. & Popel, A. S. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A 105, 13775-13780 (2008
8. Rosca, E. V., Koskimaki, J. E., Pandey, N. B., Wolff, A. C. & Popel, A. S. Development of a biomimetic peptide derived from collagen IV with antiangiogenic activity in breast cancer. Cancer Biol Ther 12, 808-817 (2011
9. Rosca, E. V., Koskimaki, J. E., Pandey, N. B., Tamiz, A. P. & Popel, A. S. Structureactivity relationship study of collagen-derived anti-angiogenic biomimetic peptides. Chem Biol Drug Des 80, 27-37 (2012
10. Rivera, C. G. et al. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem 54, 6492-6500 (2011
11. Lee, E., Pandey, N. B. & Popel, A. S. Pre-treatment of mice with tumorconditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clin Exp Metastasis 31, 67-79 (2014
12. Lee, E. et al. Breast cancer cells condition lymphatic endothelial cells within premetastatic niches to promote metastasis. Nat Commun 5, 4715 (2014
13. Oommen, S., Gupta, S. K. & Vlahakis, N. E. Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site. J Biol Chem 286, 1083-1092 (2011
14. Mitra, A. K. et al. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566-1576 (2011
15. Kabir-Salmani, M., Shiokawa, S., Akimoto, Y., Sakai, K. & Iwashita, M. The role of alpha(5)beta(1)-integrin in the IGF-I-induced migration of extravillous trophoblast cells during the process of implantation. Mol Hum Reprod 10, 91-97 (2004
16. Yu, X., Miyamoto, S. & Mekada, E. Integrin alpha 2 beta 1-dependent EGF receptor activation at cell-cell contact sites. J Cell Sci 113 (Pt 12), 2139-2147 (2000
17. Bahr, C. & Groner, B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 23, 1-14 (2005
18. Sennino, B., Ishiguro-Oonuma, T., Schriver, B. J., Christensen, J. G. & McDonald, D. M. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 73, 3692-3703 (2013
19. Xu, S. et al. CD58, a novel surface marker, promotes self-renewal of tumorinitiating cells in colorectal cancer. Oncogene (2014) doi: 10.1038/onc.2014.95. [Epub ahead of print]
20. Sloan, K. E. et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4, 73 (2004
21. Glunde, K. & Stasinopoulos, I. ADAM17: the new face of breast cancer-promoting metalloprotease activity. Cancer Biol Ther 8, 1055-1057 (2009
22. Pacher, M. et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 28, 49-59 (2007
23. Peyrat, J. P. et al. Characterization of insulin-like growth factor 1 receptors (IGF1- R) in human breast cancer cell lines. Bull Cancer 76, 311-319 (1989
24. Parr, C. & Jiang, W. G. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 119, 1176-1183 (2006
25. Sakai, K., Yamashita, J. & Ogawa, M. [A strong predictor of breast cancer- hepatocyte growth factor (HGF)]. Gan To Kagaku Ryoho 22 Suppl 1, 71-74 (1995
26. Vora, H. H. et al. Cytokeratin and vimentin expression in breast cancer. Int J Biol Markers 24, 38-46 (2009
27. Hoganson, D. M., Pryor, H. I., 2nd & Vacanti, J. P. Tissue engineering and organ structure: a vascularized approach to liver and lung. Pediatr Res 63, 520-526 (2008
28. Cao, Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 5, 735-743 (2005
29. Wilker, E. et al. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Mol Carcinog 44, 137-145 (2005
30. Thompson, A. D., 3rd & Kakar, S. S. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 579, 3195-3200 (2005
31. Gotte, M., Kersting, C., Radke, I., Kiesel, L. & Wulfing, P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 9, R8 (2007
32. Saito, Y. et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation 114, 1177-1184 (2006
33. Zhao, D. et al. Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Hum Pathol 42, 1514-1523 (2011
34. Maroun, C. R. & Rowlands, T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 142, 316-338 (2014
35. Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 47, 1231-1243 (2011
36. Etnyre, D. et al. Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther 15, 1129-1141 (2014
37. Paulson, A. K. et al. MET and ERBB2 are coexpressed in ERBB21 breast cancer and contribute to innate resistance. Mol Cancer Res 11, 1112-1121 (2013
38. Mueller, K. L. et al. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triplenegative breast cancers through paracrine activation of Met. Breast Cancer Res 14, R104 (2012
39. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10, 9-22 (2010
40. Avraamides, C. J., Garmy-Susini, B. & Varner, J. A. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8, 604-617 (2008
41. Soung, Y. H., Clifford, J. L. & Chung, J. Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression. BMB Rep 43, 311-318 (2010
42. Lin, J. et al. ADAM17 overexpression promotes angiogenesis by increasing blood vessel sprouting and pericyte number during brain microvessel development. Int J Dev Biol 55, 961-968 (2011
43. Das, S. et al. ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One 7, e50791 (2012
44. Zheng, X. et al. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8, 1045-1054 (2009
45. Gao, M. Q. et al. Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-alpha cleavage by ADAM17. Cancer Lett 336, 240-246 (2013
46. Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886 (2002
47. Rosca, E. V. et al. Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12, 1101-1116 (2011
48. Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y. & Green, J. J.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv 8, 485-504 (2011
49. Shmueli, R. B. et al. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpinderived peptide. Biomaterials 34, 7544-7551 (2013
50. Ito, Y. et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. Endocr J 60, 113-117 (2013
51. Hood, J. L., San, R. S. & Wickline, S. A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71, 3792-3801 (2011